Trial Profile

Ceritinib in Mutation and Oncogene Directed Therapy in Metastatic or Locally Advanced Anaplastic/Undifferentiated Thyroid Cancer

Status: Withdrawn prior to enrolment

Phase of Trial: Phase II

Latest Information Update: 06 Nov 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Ceritinib (Primary)
Indications Thyroid cancer
Focus Therapeutic Use

Most Recent Events

26 Jul 2019 Status changed from recruiting to withdrawn prior to enrolment as the study was on hold for protocol redesign; decided to not move forward with study
15 Jan 2019 Planned primary completion date changed from 1 Dec 2019 to 1 Dec 2020.
02 Jan 2018 Planned number of patients changed from 10 to 100.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com